Mortality after high‐risk myocardial infarction over the last 20 years: Insights from the VALIANT and PARADISE‐MI trials

Abstract

AimsThe temporal changes in clinical profiles and outcomes of high‐risk myocardial infarction survivors enrolled in clinical trials are poorly described. This study compares mortality rates, baseline characteristics, and the prognostic impact of therapies among participants of the VALIANT and PARADISE‐MI trials.Methods and resultsExclusively VALIANT participants who matched the inclusion criteria of the PARADISE‐MI trial were included in the analysis. Risk of death was compared between trials using Cox regression models. The impact of baseline characteristics and therapies on mortality was estimated by the magnitude reduction of β coefficients using Cox proportional hazards regression models. A total of 9617 VALIANT participants matched the inclusion criteria of the PARADISE‐MI trial (n = 5661). All‐cause mortality in PARADISE‐MI was less than half that in VALIANT (4.2 vs 9.9 per 100 patient‐years; hazard ratio [HR] 0.41, 95% confidence interval [CI] 0.37–0.46). This difference was reduced after adjustment for clinical variables but remained substantial (adjusted HR 0.68, 95% CI 0.58–0.80). The most important mediator of this reduction related to covariate adjustment was the use of percutaneous coronary intervention (PCI), accounting for almost half of the attenuation observed. Similar results were found for cardiovascular (CV) death, while no between‐trial significant differences were found in the non‐CV mortality risk.ConclusionsCardiovascular mortality following high‐risk myocardial infarction has significantly declined over time, while the risk for non‐CV death has remained unchanged. This improvement is partially attributable to advancements in CV care, particularly the use of PCI. Continued efforts to implement guidelines and standardize the quality of care are needed to sustain this positive trend.